Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study

Key Points

• The findings indicate positive efficacy and safety outcomes for lenacapavir, teropavimab, and zinlirvimab.
• Primary outcomes were assessed at week 26 in this phase 2 randomized controlled trial.
• Participants received one of the three active medications over a specified treatment period.
• These results may support the future use of these agents in clinical practice, warranting further research.

Abstract